// App-Quantinova.ai

889 : IOA-244 is a non-ATP-competitive, highly selective, tolerable phosphoinositide 3-kinase delta inhibitor that directly targets solid tumours and breaks immune tolerance

Researchers

Presenter

  • Giusy Di Conza

Principal Investigators

  • Lars van der Veen

  • Chiara Tarantelli

  • Francesco Bertoni

  • Amy Fraser

  • Pritom Shah

  • Simon Tiede

  • Laura Tesmer

  • Gerhard Hummer

  • Oscar Vadas

  • Michael Lahn

  • Nomanbhoy Tyzoonn

  • Zoe Johnson

Medical Centers

  • University Hospital Geneva, Geneva, Switzerland

  • Institute of Oncology Research, Faculty of Biomedical Sciences,USI,Bellinzona,Switzerland

  • Activix, La Jolla, CA, United States

  • iOnctura SA, Geneva, Switzerland

  • Cancer Research Horizon, London, UK

  • Max Planck Institute of Biophysics, Frankfurt, Germany

Locations

  • Switzerland

  • United States

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved